Each additional hour spent napping during the day tracks with a roughly 13 percent higher risk of dying from any cause, according to research synthesized by lead author Chenlu Gao and reported by Harvard. The finding draws on prospective cohort data, including the EPIC-Norfolk study that followed a British population for approximately 13 years, and on dose-response meta-analyses showing that naps of 60 minutes or longer carry the steepest risk. For the tens of millions of adults who nap regularly, the statistic raises a pointed question: is the nap itself harmful, or is it a signal that something else has already gone wrong?
Why the 13 Percent Per-Hour Napping Figure Demands Attention
The number is striking because it is not a one-off result from a single questionnaire. The EPIC-Norfolk cohort, published in the American Journal of Epidemiology, tracked self-reported napping habits and mortality outcomes over roughly 13 years in a large British population. That study found higher all-cause mortality risk for people who reported napping less than one hour per day and even greater risk among those napping one hour or more. The association was especially pronounced for respiratory deaths, a pattern that suggests the link may reflect underlying cardiopulmonary disease rather than the act of sleeping midday.
A separate dose-response meta-analysis of prospective studies confirmed the pattern, showing that naps commonly lasting 60 minutes or more per day carried higher all-cause and cardiovascular mortality risk. A third systematic review pooling self-reported napping data across multiple cohorts found consistent relative-risk elevations, though effect sizes varied by age, sex, and baseline health.
One plausible mechanism ties these findings together: long daytime naps may fragment nighttime sleep continuity, particularly in adults over 65. Broken overnight sleep is already linked to higher inflammation and impaired cognition the following day. If excessive napping disrupts the deep-sleep phases that regulate immune function and cardiovascular repair, the mortality signal could reflect a downstream chain rather than a direct cause. Testing that hypothesis would require linking multi-day wearable sleep tracking to next-day inflammatory and cognitive markers in an existing aging cohort, a study design that current actigraphy technology makes feasible but that has not yet been published.
Cohort Data and Meta-Analyses Behind the Mortality Signal
The strongest evidence comes from three layers of research. The EPIC-Norfolk cohort provided individual-level prospective data, with participants reporting their napping behavior and then being followed for deaths from all causes, cardiovascular disease, cancer, and respiratory illness. The study controlled for age, sex, smoking, physical activity, and other standard confounders. Its finding that respiratory mortality showed the strongest napping association is significant because respiratory conditions such as chronic obstructive pulmonary disease and sleep apnea are themselves causes of daytime sleepiness. That creates a chicken-and-egg problem: people who nap more may already be sicker.
The dose-response meta-analysis added statistical power by pooling results across multiple cohorts. Its key contribution was showing a graded relationship: risk climbed with nap duration, and the threshold for clearly elevated risk sat at about 60 minutes per day. Shorter naps showed weaker or nonsignificant associations in some analyses, which is why the per-hour framing matters. It is not that any nap is dangerous. The data point toward longer, habitual napping as the behavior most consistently tied to worse outcomes.
A third systematic review of self-reported napping and mortality reinforced these patterns while also flagging the limits of self-report. People estimate their own nap duration poorly, and recall bias can distort exposure classification. That weakness is part of what makes the newer per-hour actigraphy-based estimate, as summarized by Chenlu Gao, analytically valuable: wearable devices measure sleep objectively, removing the guesswork that plagued earlier questionnaire-based cohorts.
Gao, the lead author of the analysis discussed by Harvard, framed the result carefully. The approximately 13 percent per-hour figure and a separate approximately 7 percent increase per additional nap suggest a dose-dependent relationship. But Gao emphasized that naps may function as a marker of underlying disease rather than a direct cause of death. That distinction matters for anyone tempted to treat the headline number as a reason to set an alarm.
Gaps in the Evidence and What Nappers Should Watch For
Several questions remain open. The cause-specific mortality breakdown tied to the newer per-hour finding has not been reported in detail beyond the institutional summary. Without knowing whether the 13 percent figure is driven primarily by cardiovascular, respiratory, or other causes of death, clinicians cannot translate it into targeted screening advice. For example, if the excess risk is concentrated in respiratory deaths, that would strengthen the case for evaluating heavy nappers for sleep apnea or chronic lung disease. If instead cardiovascular events dominate, blood pressure, lipid control, and arrhythmia screening might be the more logical focus.
Confounder control is another gap. Depression, undiagnosed sleep apnea, and medication side effects all increase daytime sleepiness and independently raise mortality risk. The EPIC-Norfolk study and the meta-analyses adjusted for standard variables, but none had access to polysomnography or detailed psychiatric assessments for all participants. That means residual confounding is likely: people who nap the most may also be those with the heaviest burden of unmeasured illness.
There is also the question of reverse causality. In aging populations, subtle declines in cardiopulmonary function, early neurodegenerative changes, or chronic inflammatory states can precede formal diagnosis by years. Daytime fatigue and a growing need for naps may be among the earliest, most nonspecific signs. In that scenario, naps are less a cause of mortality than a symptom of an already unfolding disease process.
Measurement limitations further complicate interpretation. Most of the foundational work relied on single-time-point self-reports of “usual” napping. People’s routines change, especially as they retire, develop new medical conditions, or start and stop medications. A baseline report of one-hour daily naps may not reflect behavior five or ten years later, yet mortality risk is attributed to that initial snapshot. The newer actigraphy-based analyses partially address this by capturing real-time behavior, but they are still relatively short-term and have not yet linked device-recorded naps to long-run outcomes with the same follow-up length as EPIC-Norfolk.
For individual nappers, the practical question is what to do with this uncertainty. The current evidence does not justify a blanket warning against all daytime sleep. Short, intentional naps of 20 to 30 minutes, especially earlier in the afternoon, are unlikely to carry the same risk profile as unplanned, hour-long dozing that recurs day after day. In fact, controlled laboratory studies outside the mortality literature have documented performance and alertness benefits from brief naps, particularly in people who are sleep-deprived.
Where concern is warranted is at the extremes. Adults who find themselves needing more than an hour of daytime sleep most days of the week, or who fall asleep unintentionally while reading, watching television, or riding as a passenger, should treat that pattern as a health signal. Rather than focusing on the nap itself as toxic, the more productive step is to ask why so much extra sleep seems necessary.
Clinicians can use heavy napping as a prompt to screen for common, treatable contributors. Sleep apnea is a prime example: loud snoring, witnessed breathing pauses, morning headaches, and persistent daytime sleepiness together justify a formal sleep study. Heart failure, chronic obstructive pulmonary disease, poorly controlled diabetes, thyroid disorders, and major depression all belong on the differential diagnosis list when a patient reports escalating nap needs. A medication review can also be revealing, as sedating drugs for allergies, pain, or anxiety may be driving the behavior.
At the same time, improving nighttime sleep quality remains a central strategy. Regular bed and wake times, limiting caffeine and alcohol late in the day, and reducing late-evening screen exposure can consolidate nocturnal sleep and reduce the drive to nap. For people who still benefit from daytime rest, keeping naps short and earlier in the afternoon may help preserve the restorative deep sleep that occurs later in the night.
The emerging per-hour mortality estimate underscores that sleep timing and structure matter, not just total hours in bed. Long, frequent naps appear to travel with higher risk, but the weight of evidence still points toward naps as a red flag rather than a direct hazard. Until larger, device-based cohorts can disentangle cause from correlation, the most reasonable response is not to fear the occasional catnap, but to pay attention when daytime sleep becomes a dominant feature of daily life-and to treat that change as an opportunity for earlier detection of underlying disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
